variable_name	code_list	definition
budget_cpp_dstb		Average cost of drugs budgeted per patient for drug-susceptible TB treatment, excluding buffer stock (US Dollars)
budget_cpp_mdr		Average cost of drugs budgeted per patient for MDR-TB treatment, excluding buffer stock (US Dollars)
budget_cpp_tpt		Average cost of drugs budgeted per patient for  TB preventive treatment, excluding buffer stock (US Dollars)
budget_cpp_xdr		Average cost of drugs budgeted per patient for XDR-TB treatment, excluding buffer stock (US Dollars)
budget_fld		Budget required for drugs to treat drug-susceptible TB (US Dollars)
budget_lab		Budget required for laboratory infrastructure, equipment and supplies (US Dollars)
budget_mdrmgt		Budget required for programme costs to treat drug-resistant TB (US Dollars)
budget_orsrvy		Budget required for operational research and surveys (US Dollars)
budget_oth		Budget required for all other budget line items (US Dollars)
budget_patsup		Budget required for patient support (US Dollars)
budget_prog		Budget required for programme costs to treat drug-susceptible TB (US Dollars)
budget_sld		Budget required for drugs to treat drug-resistant TB (US Dollars)
budget_staff		Budget required for National TB Programme staff (central unit staff and subnational TB staff)  (US Dollars)
budget_tbhiv		Budget required for collaborative TB/HIV activities (US Dollars)
budget_tot		Total budget required (US Dollars)
budget_tpt		Budget required for TB preventive treatment: drugs (US Dollars)
cf_fld		Expected funding for drugs to treat drug-susceptible TB (US Dollars)
cf_lab		Expected funding for laboratory infrastructure, equipment and supplies (US Dollars)
cf_mdrmgt		Expected funding for programme costs to treat drug-resistant TB (US Dollars)
cf_orsrvy		Expected funding for operational research and surveys (US Dollars)
cf_oth		Expected funding for all other budget line items (US Dollars)
cf_patsup		Expected funding for patient support (US Dollars)
cf_prog		Expected funding for programme costs to treat drug-susceptible TB (US Dollars)
cf_sld		Expected funding for drugs to treat drug-resistant TB (US Dollars)
cf_staff		Expected funding for National TB Programme staff (central unit staff and subnational TB staff)  (US Dollars)
cf_tbhiv		Expected funding for collaborative TB/HIV activities (US Dollars)
cf_tot		Total expected funding for all budget line items (US Dollars)
cf_tot_domestic		Expected funding from domestic sources, including loans (US Dollars)
cf_tot_gf		Expected funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria (US Dollars)
cf_tot_grnt		Expected funding from other sources (US Dollars)
cf_tot_sources		Total expected funding from all sources (US Dollars)
cf_tot_usaid		Expected funding from USAID (US Dollars)
cf_tpt		Expected funding for TB preventive treatment drugs (US Dollars)
tx_dstb		Number of patients expected to start drug-susceptible TB treatment
tx_mdr		Number of patients expected to start MDR-TB treatment
tx_tpt		Number of patients expected to start TB preventive treatment
tx_xdr		Number of patients expected to start XDR-TB treatment
bmu		Number of TB Basic Management Units in the country
bmu_community_impl		Number of TB Basic Management Units which implemented community-based referrals or any form of community treatment adherence support
bmu_ref_data		Number of Basic Management Units with data on referrals by community health workers / community volunteers
bmu_rxsupport_data		Number of Basic Management Units with data on community treatment adherence support
bmu_rxsupport_data_coh		Total number of patients who started TB treatment in the Basic Management Units with data on community treatment adherence support
community_data_available	0=No; 1=Yes	Are data available on community-based referrals or any form of community treatment adherence support?
notified_ref		Total number of new and relapse TB cases notified in the Basic Management Units with data on referrals by community health workers
notified_ref_community		Total number of new and relapse TB cases referred by community health workers / community volunteers in the Basic Management Units with data on referrals by community health workers
rxsupport_community_coh		Total number of patients who started TB treatment and who received any form of treatment adherence support from community health workers / community volunteers in the Basic Management Units with data on community treatment adherence support
rxsupport_community_succ		Total number of patients who were cured or who completed treatment among the cases who started TB treatment and who received any form of treatment adherence support from community health workers / community volunteers in the Basic Management Units with data on community treatment adherence support
newinc_con		(If screen_data_available=60) Number of household contacts of bacteriologically-confirmed pulmonary new and relapse TB cases
newinc_con_prevtx		(If prevtx_data_available=60) Number of household contacts of bacteriologically-confirmed pulmonary new and relapse TB cases notified in the reporting year who were started on TB preventive treatment
newinc_con_screen		(If screen_data_available=60) Number of household contacts of bacteriologically-confirmed pulmonary new and relapse TB cases who were evaluated for active TB and latent TB
newinc_con04_prevtx		(If prevtx_data_available=60) Number of children aged under 5 started on TB preventive treatment who are household contacts of bacteriologically-confirmed new and relapse TB cases notified
newinc_con5plus_prevtx		(If prevtx_5plus_data_available=60) Number of children aged 5 years and above, adolescents and adults started on TB preventive therapy who are household contacts of bacteriologically-confirmed new and relapse TB cases notified
prevtx_5plus_data_available	0=No; 60= Yes available from the routine surveillance system; 61=Yes estimated from a review of a random sample of medical records or treatment cards of TB patients representative of the national TB patient population	Are data available on the number of children aged 5 years and above, adolescents and adults who are household contacts of TB cases and started on TB preventive therapy?
prevtx_data_available	0=No; 60= Yes available from the routine surveillance system; 61=Yes estimated from a review of a random sample of medical records or treatment cards of TB patients representative of the national TB patient population	Are data available on the number of household contacts of TB cases started on TB preventive treatment?
prevtx_short_data_available	0=No; 1=Yes; 2=Not applicable; 194=Not used	Are data available on the number of patients treated using shorter TB preventive treatment regimens containing rifampicin or rifapentine?
prevtx_short_rifamycin		(if prevtx_short_data_available=1) Total number of individuals started on shorter TB preventive treatment regimens containing rifampicin or rifapentine in the reporting year
ptsurvey_newinc		(If prevtx_data_available=61) Number of bacteriologically-confirmed TB new and relapse cases notified in the reporting year whose medical records or treatment cards were included in a survey
ptsurvey_newinc_5plus		(If prevtx_5plus_data_available=61) Number of bacteriologically-confirmed TB new and relapse cases notified in the reporting year whose medical records or treatment cards were included in a survey
ptsurvey_newinc_con_prevtx		(If prevtx_data_available=61) Number of household contacts of the TB cases surveyed in ptsurvey_newinc who were started on TB preventive treatment.
ptsurvey_newinc_con04_prevtx		(If prevtx_data_available=61) Number of children aged under 5 started on TB preventive treatment who are household contacts of the TB cases in ptsurvey_newinc
ptsurvey_newinc_con5plus_prevtx		(If prevtx_5plus_data_available=61) Number of children aged 5 years and above, adolescents and adults started on TB preventive therapy who are household contacts of the TB cases in ptsurvey_newinc_5plus
rev_newinc		(If screen_data_available=61) Number of bacteriologically-confirmed pulmonary new and relapse TB cases whose medical records or treatment cards were included in the review
rev_newinc_con		(If screen_data_available=61) Number of household contacts identified from the bacteriologically-confirmed pulmonary new and relapse TB cases whose medical records or treatment cards were included in the review
rev_newinc_con_screen		(If screen_data_available=61) Number of household contacts who were evaluated for active TB and latent TB identified from the bacteriologically-confirmed pulmonary new and relapse TB cases whose medical records or treatment cards were included in the review
screen_data_available	0=No; 60= Yes available from the routine surveillance system; 61=Yes estimated from a review of a random sample of medical records or treatment cards of TB patients representative of the national TB patient population; 5=Not applicable	Are data available on the number of household contacts of TB cases who were evaluated for TB?
country		Country or territory name
iso_numeric		ISO numeric country/territory code
iso2		ISO 2-character country/territory code
iso3		ISO 3-character country/territory code
age_group	0-4=0-4 years; 5-14=5-14 years; 15-24=15-24 years ..etc; 15plus=15 years and above; 65plus=65 years and above; all=All ages;	Age group (in years)
best		Best estimate
hi		High bound of estimate
lo		Low bound of estimate
measure	inc = incidence	The measure of TB burden being estimated
risk_factor	alc=Harmful use of alcohol; dia=Diabetes; hiv=HIV; smk=Smoking; und=Undernourishment; all=All (not disaggregated by specific risk factors)	Cases attributable to a specific risk factor
sex	a=All (females and males); f=Females; m=Males	Sex
unit	num=absolute number	The unit of measurement
dst_rlt_hr_new		Number of new bacteriologically confirmed pulmonary TB patients with test results for rifampicin and isoniazid and with resistance to isoniazid (regardless of result for rifampicin)
dst_rlt_hr_ret		Number of previously treated bacteriologically confirmed pulmonary TB patients with test results for rifampicin and isoniazid and with resistance to isoniazid (regardless of result for rifampicin)
dst_rlt_new		Drug resistance surveillance: Among new pulmonary TB patients with positive identification for M. Tuberculosis complex (confirmed by culture and/or line-probe assay): number of patients with available drug susceptibility testing results for isoniazid and rifampicin
dst_rlt_ret		Drug resistance surveillance: Among patients previously treated for TB with positive identification for M. Tuberculosis complex (confirmed by culture and/or line-probe assay): number of patients with available drug susceptibility testing results for isoniazid and rifampicin
dst_rlt_rr_new		Number of new bacteriologically confirmed pulmonary TB patients with test results for rifampicin and isoniazid and with resistance to rifampicin (regardless of result for isoniazid)
dst_rlt_rr_ret		Number of previously treated bacteriologically confirmed pulmonary TB patients with test results for rifampicin and isoniazid and with resistance to rifampicin (regardless of result for isoniazid)
mdr_dst_rlt		Drug resistance surveillance: Total number of pulmonary MDR-TB patients with drug susceptibility test results for any fluoroquinolone and any second-line injectable agent
mdr_new		Drug resistance surveillance: Among new TB patients with available drug susceptibility testing results (variable dst_rlt_new):  number of patients with resistance to isoniazid and rifampicin  (MDR-TB)
mdr_ret		Drug resistance surveillance: Among patients previously treated for TB with available drug susceptibility testing results (variable dst_rlt_ret):  number of patients with resistance to isoniazid and rifampicin  (MDR-TB)
nrr_014		Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and who are aged 0-14 years
nrr_15plus		Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and who are aged 15 years and over
nrr_ageunk		Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and whose age is unknown
nrr_hivneg		Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and who are HIV-negative
nrr_hivpos		Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and who are HIV-positive
nrr_hivunk		Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and whose HIV status is unknown
pulm_labconf_new		Number of new bacteriologically confirmed pulmonary TB cases
pulm_labconf_ret		Number of previously treated bacteriologically confirmed pulmonary TB cases
pulm_labconf_unk		Number of bacteriologically confirmed pulmonary TB cases with unknown TB treatment history
r_rlt_new		Number of new bacteriologically confirmed pulmonary TB patients with test results for rifampicin
r_rlt_ret		Number of previously treated bacteriologically confirmed pulmonary TB patients with test results for rifampicin
rr_014		Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and who are aged 0-14 years
rr_15plus		Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and who are aged 15 years and over
rr_ageunk		Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and whose age is unknown
rr_dr_2li		Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and resistance to second-line injectable agents
rr_dr_fq		Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and resistance to fluoroquinolones
rr_dr_fq_2li		Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and resistance to both fluoroquinolones and second-line injectable agents
rr_ds_fq2li		Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and susceptible to both fluoroquinolones and second-line injectable agents
rr_dst_rlt		Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and with test results for any fluoroquinolone and any second-line injectable agent
rr_dst_rlt_fq		Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and with test results for any fluoroquinolone
rr_fqr		Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and resistance to fluoroquinolones
rr_hivneg		Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and who are HIV-negative
rr_hivpos		Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and who are HIV-positive
rr_hivunk		Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and whose HIV status is unknown
rr_new		Number of new bacteriologically confirmed pulmonary TB patients with resistance to rifampicin (RR-TB)
rr_ret		Number of previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin (RR-TB)
xdr		Drug resistance surveillance: Among pulmonary MDR-TB patients with drug susceptibility test results for any fluoroquinolone (FQ) and any second-line injectable agent (2LI) (variable mdr_dst_rlt): number with any resistance to both FQ and 2LI (i.e. XDR-TB)
c_cdr		Case detection rate (all forms) [also known as TB treatment coverage], percent
c_cdr_hi		Case detection rate (all forms) [also known as TB treatment coverage], percent, high bound
c_cdr_lo		Case detection rate (all forms) [also known as TB treatment coverage], percent, low bound
c_newinc_100k		Case notification rate, which is the total of new and relapse cases and cases with unknown previous TB treatment history per 100 000 population (calculated)
cfr		Estimated TB case fatality ratio
cfr_hi		Estimated TB case fatality ratio: high bound
cfr_lo		Estimated TB case fatality ratio: low bound
cfr_pct		Estimated TB case fatality ratio expressed as a percentage
cfr_pct_hi		Estimated TB case fatality ratio: high bound expressed as a percentage
cfr_pct_lo		Estimated TB case fatality ratio: low bound expressed as a percentage
e_inc_100k		Estimated incidence (all forms) per 100 000 population
e_inc_100k_hi		Estimated incidence (all forms) per 100 000 population, high bound
e_inc_100k_lo		Estimated incidence (all forms) per 100 000 population, low bound
e_inc_num		Estimated number of incident cases (all forms)
e_inc_num_hi		Estimated number of incident cases (all forms), high bound
e_inc_num_lo		Estimated number of incident cases (all forms), low bound
e_inc_rr_num		Estimated incidence of rifampicin resistant TB (absolute number)
e_inc_rr_num_hi		Estimated incidence of rifampicin resistant TB (absolute number): high bound
e_inc_rr_num_lo		Estimated incidence of rifampicin resistant TB (absolute number): low bound
e_inc_tbhiv_100k		Estimated incidence of TB cases who are HIV-positive per 100 000 population
e_inc_tbhiv_100k_hi		Estimated incidence of TB cases who are HIV-positive per 100 000 population, high bound
e_inc_tbhiv_100k_lo		Estimated incidence of TB cases who are HIV-positive per 100 000 population, low bound
e_inc_tbhiv_num		Estimated incidence of TB cases who are HIV-positive
e_inc_tbhiv_num_hi		Estimated incidence of TB cases who are HIV-positive, high bound
e_inc_tbhiv_num_lo		Estimated incidence of TB cases who are HIV-positive, low bound
e_mdr_pct_rr		Estimated percentage of rifampicin resistant TB cases that have MDR-TB
e_mdr_pct_rr_new		Estimated percentage of new rifampicin resistant TB cases that have MDR-TB
e_mdr_pct_rr_ret		Estimated percentage of previously treated rifampicin resistant TB cases that have MDR-TB
e_mort_100k		Estimated mortality of TB cases (all forms) per 100 000 population
e_mort_100k_hi		Estimated mortality of TB cases (all forms) per 100 000 population, high bound
e_mort_100k_lo		Estimated mortality of TB cases (all forms) per 100 000 population, low bound
e_mort_exc_tbhiv_100k		Estimated mortality of TB cases (all forms, excluding HIV) per 100 000 population
e_mort_exc_tbhiv_100k_hi		Estimated mortality of TB cases (all forms, excluding HIV), per 100 000 population, high bound
e_mort_exc_tbhiv_100k_lo		Estimated mortality of TB cases (all forms, excluding HIV), per 100 000 population, low bound
e_mort_exc_tbhiv_num		Estimated number of deaths from TB (all forms, excluding HIV)
e_mort_exc_tbhiv_num_hi		Estimated number of deaths from TB (all forms, excluding HIV), high bound
e_mort_exc_tbhiv_num_lo		Estimated number of deaths from TB (all forms, excluding HIV), low bound
e_mort_num		Estimated number of deaths from TB (all forms)
e_mort_num_hi		Estimated number of deaths from TB (all forms), high bound
e_mort_num_lo		Estimated number of deaths from TB (all forms), low bound
e_mort_tbhiv_100k		Estimated mortality of TB cases who are HIV-positive, per 100 000 population
e_mort_tbhiv_100k_hi		Estimated mortality of TB cases who are HIV-positive, per 100 000 population, high bound
e_mort_tbhiv_100k_lo		Estimated mortality of TB cases who are HIV-positive, per 100 000 population, low bound
e_mort_tbhiv_num		Estimated number of deaths from TB in people who are HIV-positive
e_mort_tbhiv_num_hi		Estimated number of deaths from TB in people who are HIV-positive, high bound
e_mort_tbhiv_num_lo		Estimated number of deaths from TB in people who are HIV-positive, low bound
e_pop_num		Estimated total population number
e_rr_in_notified_labconf_pulm		Estimated number of RR-TB cases among notified bacteriologically confirmed pulmonary TB cases
e_rr_in_notified_labconf_pulm_hi		Estimated number of RR-TB cases among notified bacteriologically confirmed pulmonary TB cases: high bound
e_rr_in_notified_labconf_pulm_lo		Estimated number of RR-TB cases among notified bacteriologically confirmed pulmonary TB cases: low bound
e_rr_pct_new		Estimated percentage of new TB cases with rifampicin resistant TB
e_rr_pct_new_hi		Estimated percentage of new TB cases with rifampicin resistant TB: high bound
e_rr_pct_new_lo		Estimated percentage of new TB cases with rifampicin resistant TB: low bound
e_rr_pct_ret		Estimated percentage of previously treated TB cases with rifampicin resistant TB
e_rr_pct_ret_hi		Estimated percentage of previously treated TB cases with rifampicin resistant TB: high bound
e_rr_pct_ret_lo		Estimated percentage of previously treated TB cases with rifampicin resistant TB: low bound
e_tbhiv_prct		Estimated HIV in incident TB (percent)
e_tbhiv_prct_hi		Estimated HIV in incident TB (percent), high bound
e_tbhiv_prct_lo		Estimated HIV in incident TB (percent), low bound
source_drs_coverage_new		Indicates whether national or subnational data from drug resistance surveys or surveillance was used to estimate the proportion of new TB cases with MDR-TB
source_drs_coverage_ret		Indicates whether national or subnational data from drug resistance surveys or surveillance was used to estimate the proportion of previously treated TB cases with MDR-TB
source_drs_year_new		Year of drug resistance surveillance, survey or model used to estimate proportion of new TB cases with MDR-TB
source_drs_year_ret		Year of drug resistance surveillance, survey or model used to estimate proportion of previously treated TB cases with MDR-TB
source_rr_new		Method used to estimate proportion of new TB patients with rifampicin-resistant TB
source_rr_ret		Method used to estimate proportion of previously treated TB patients with rifampicin-resistant TB
exp_cpp_dstb		Average cost of drugs spent per patient starting first-line TB treatment, excluding buffer stock (US Dollars)
exp_cpp_mdr		Average cost of drugs spent per patient starting second-line treatment for MDR-TB, excluding buffer stock (US Dollars)
exp_cpp_tpt		Average cost of drugs spent per person starting TB preventive treatment, excluding buffer stock (US Dollars)
exp_cpp_xdr		Average cost of drugs spent per patient starting XDR-TB treatment, excluding buffer stock (US Dollars)
exp_fld		Actual expenditure on drugs to treat drug-susceptible TB (US Dollars)
exp_lab		Actual expenditure on laboratory infrastructure, equipment and supplies (US Dollars)
exp_mdrmgt		Actual expenditure on programme costs to treat drug-resistant TB (US Dollars)
exp_orsrvy		Actual expenditure on operational research and surveys (US Dollars)
exp_oth		Actual expenditure on all other budget line items (US Dollars)
exp_patsup		Actual expenditure on patient support (US Dollars)
exp_prog		Actual expenditure on programme costs to treat drug-susceptible TB (US Dollars)
exp_sld		Actual expenditure on drugs to treat drug-resistant TB (US Dollars)
exp_staff		Actual expenditure on National TB Programme staff (central unit staff and subnational TB staff)  (US Dollars)
exp_tbhiv		Actual expenditure on collaborative TB/HIV activities (US Dollars)
exp_tot		Total actual expenditure (US Dollars)
exp_tpt		Actual expenditure on drugs for TB preventive treatment (US Dollars)
hcfvisit_dstb		Typical number of visits to a health facility after diagnosis for patients starting first-line TB treatment
hcfvisit_mdr		Typical number of visits to a health facility after diagnosis for patients starting MDR-TB/XDR-TB treatment
hosp_type_mdr	2=Not applicable; 140=Primary-level hospital; 141=Secondary-level hospital; 142= Tertiary-level hospital	Type of facility most often used if MDR-TB patients are hospitalized
hospd_dstb_dur		Estimated average duration of stay if patients starting first-line TB treatment are hospitalized (days)
hospd_dstb_prct		Estimated percentage of patients starting first-line TB treatment that are hospitalized (%)
hospd_mdr_dur		Estimated average duration of stay if patients starting MDR-TB/XDR-TB treatment are hospitalized (days)
hospd_mdr_prct		Estimated percentage of patients starting MDR-TB/XDR-TB treatment that are hospitalized (%)
rcvd_fld		Funding received for drugs to treat drug-susceptible TB (US Dollars)
rcvd_lab		Funding received for laboratory infrastructure, equipment and supplies (US Dollars)
rcvd_mdrmgt		Funding received for programme costs to treat drug-resistant TB (US Dollars)
rcvd_orsrvy		Funding received for operational research and surveys (US Dollars)
rcvd_oth		Funding received for all other budget line items (US Dollars)
rcvd_patsup		Funding received for patient support (US Dollars)
rcvd_prog		Funding received for programme costs to treat drug-susceptible TB (US Dollars)
rcvd_sld		Funding received for drugs to treat drug-resistant TB (US Dollars)
rcvd_staff		Funding received for National TB Programme staff (central unit staff and subnational TB staff)  (US Dollars)
rcvd_tbhiv		Funding received for collaborative TB/HIV activities (US Dollars)
rcvd_tot		Total funding received for all budget line items (US Dollars)
rcvd_tot_domestic		Funding received from domestic sources, including loans (US Dollars)
rcvd_tot_gf		Funding received from the Global Fund to Fight AIDS, Tuberculosis and Malaria (US Dollars)
rcvd_tot_grnt		Funding received from other sources (US Dollars)
rcvd_tot_sources		Total funding received from all sources (US Dollars)
rcvd_tot_usaid		Funding received from USAID (US Dollars)
rcvd_tpt		Funding received for drugs for TB preventive treatment (US Dollars)
collab_private_lab	0=No; 1=yes	Were any non-NTP laboratories in the private sector (including NGOs) collaborating with the NTP?
collab_public_lab	0=No; 1=yes	Were any non-NTP laboratories in the public sector collaborating with the NTP?
culture		Number of sites providing TB diagnostic services using culture at the end of the reporting year
dst		Number of sites providing phenotypic drug susceptibility testing for first-line drugs only at the end of the reporting year
dst_eqa_pass		Number of sites providing phenotypic drug susceptibility testing for first-line drugs only that demonstrated proficiency by panel testing
lab_cul		Number of laboratories providing TB diagnostic services using culture
lab_dst		Number of laboratories providing TB diagnostic services using drug susceptibility testing
lab_dst_eqa		Number of drug susceptibility testing laboratories for which External Quality Assessment (EQA) was carried out
lab_dst_eqa_pass		Number of drug susceptibility testing laboratories which demonstrated acceptable performance
lab_lpa		Number of laboratories providing TB diagnostic services using Line Probe Assay (LPA) rifampicin
lab_lpa_eqa		Number of Line Probe Assay (LPA) rifampicin  laboratories for which External Quality Assessment (EQA) was carried out
lab_lpa_eqa_pass		Number of Line Probe Assay (LPA) rifampicin laboratories which demonstrated acceptable performance
lab_sm		Number of laboratories providing TB diagnostic services using smear microscopy
lab_sm_eqa		Number of smear microscopy laboratories for which External Quality Assessment (EQA) was carried out
lab_sm_eqa_pass		Number of smear microscopy laboratories which demonstrated acceptable performance
lab_sm_led		Number of laboratories providing TB diagnostic services using LED microscopes for smear microscopy
lab_xpert		Number of laboratories providing TB diagnostic services using xpert MTB/RIF
lab_xpert_eqa		Number of laboratories providing TB diagnostic services using xpert MTB/RIF for which External Quality Assessment (EQA) was carried out
lpa		Number of sites providing Line Probe Assay services at the end of the reporting year
lpa_eqa_pass		Number of sites providing Line Probe Assay services that demonstrated proficiency by panel testing
nrl	0=No; 1=yes	Was there a national reference laboratory or laboratories (NRL)?
nrl_iso15189	0=No; 1=yes	Has the national reference laboratory (or national reference laboratories) achieved national or international accreditation according to the ISO 15189 standard?
nrl_qms	0=No; 1=yes	Has a formal quality management system towards achieving laboratory accreditation been implemented at the National Reference Laboratory?
nrl_srl_link	0=No; 1=yes	Has a formal link been established between the National Reference Laboratory and a partner Supranational Reference Laboratory?
qms	0=No; 1=yes	Is a formal quality management system towards achieving accreditation being implemented in all laboratories conducting culture, LPA and/or DST?
sldst		Number of sites providing phenotypic drug susceptibility testing for first-line drugs and second-line drugs at the end of the reporting year
sldst_avail_incntry	0=No; 1=yes	Was second-line drug susceptibility testing available within the country for TB National Treatment Programme patients?
sldst_avail_outcntry	0=No; 1=yes	Was second-line drug susceptibility testing available outside the country for TB National Treatment Programme patients?
sldst_eqa_pass		Number of sites providing phenotypic drug susceptibility testing for first-line drugs and second-line drugs that demonstrated proficiency by panel testing
sllpa		Number of sites providing Line Probe Assay (LPA) services for rifampicin, isoniazid, fluoroquinolones, second-line injectables
sllpa_eqa_pass		Number of sites providing Line Probe Assay (LPA) services for rifampicin, isoniazid, fluoroquinolones, second-line injectables that demonstrated proficiency by panel testing
smear		Number of sites providing TB diagnostic services using smear microscopy at the end of the reporting year
smear_eqa		Number of sites providing TB diagnostic services using smear microscopy covered by a comprehensive EQA system
xpert		Number of sites providing TB diagnostic services using Xpert MTB/RIF at the end of the reporting year
xpert_eqa		Number of sites providing TB diagnostic services using Xpert MTB/RIF covered by a comprehensive EQA system
xpert_etrans		Number of sites using Xpert MTB/RIF which transmit results automatically to clinicians and to an information management system
 e_prevtx_kids_pct		Estimated % of children received TB preventive therapy aged under 5 who are household contacts of TB cases and who are eligible for TB preventive therapy
 e_prevtx_kids_pct_hi		Estimated % of children received TB preventive therapy aged under 5 who are household contacts of TB cases and who are eligible for TB preventive therapy: High bound
 e_prevtx_kids_pct_lo		Estimated % of children received TB preventive therapy aged under 5 who are household contacts of TB cases and who are eligible for TB preventive therapy: Low bound
e_hh_size		Estimated average household size
e_prevtx_eligible		Estimated number of children aged under 5 who are household contacts of TB cases who are eligible for TB preventive therapy
e_prevtx_eligible_hi		Estimated number of children aged under 5 who are household contacts of TB cases who are eligible for TB preventive therapy: high bound
e_prevtx_eligible_lo		Estimated number of children aged under 5 who are household contacts of TB cases who are eligible for TB preventive therapy: low bound
source_hh		Source of estimate of average household size
tbhiv_sentin_cil		Lower limit (95% confidence interval) of prevalence (%) of HIV in TB patients estimated using sentinel sites
tbhiv_sentin_ciu		Upper limit (95% confidence interval) of prevalence (%) of HIV in TB patients estimated using sentinel sites
tbhiv_sentin_prev		Prevalence (%) of HIV in TB patients estimated using sentinel sites
tbhiv_sentin_yr		Year in which prevalence of HIV in TB patients was estimated using sentinel sites
tbhiv_surv_cil		Lower limit (95% confidence interval) of prevalence (%) of HIV in TB patients estimated using nationwide representative surveys
tbhiv_surv_ciu		Upper limit (95% confidence interval) of prevalence (%) of HIV in TB patients estimated using nationwide representative surveys
tbhiv_surv_prev		"Prevalence (%) of HIV in TB patients estimated using nationwide representative
surveys"
tbhiv_surv_yr		Year in which prevalence of HIV in TB patients was estimated using nationwide representative surveys
agegroup_option	220=all defined in 2013 reporting framework plus 4-9 10-14 15-19 20-24 age groups; 221=all; 222=all except for 5-9 and 10-14 age groups; 223=only 0-4 5-14 and 15+ age groups	The set of age groups by which notifications have been disaggregated
all_conf_xdr		Number of laboratory-confirmed XDR-TB cases identified in the current year (including in MDR cases diagnosed in previous years).
c_newinc		Total of new and relapse cases and cases with unknown previous TB treatment history
conf_mdr		Number of laboratory-confirmed MDR-TB cases identified
conf_mdr_tx		Number of laboratory-confirmed MDR-TB patients who started treatment for MDR-TB
conf_rrmdr		Number of laboratory-confirmed RR-TB or MDR-TB cases identified
conf_rrmdr_tx		Number of laboratory-confirmed rifampicin-resistant (RR-TB) or multidrug-resistant TB (MDR-TB) patients who started treatment for MDR-TB
conf_xdr_tx		Number of laboratory-confirmed XDR-TB patients who started treatment for XDR-TB
hiv_art		HIV-positive TB patients started or continued on antiretroviral therapy (ART)
hiv_cpt		HIV-positive TB patients started or continued on co-trimoxazole preventive therapy (CPT)
hiv_ipt		People living with HIV newly enrolled in HIV treatment who started treatment for latent TB infection
hiv_ipt_reg_all		People living with HIV currently enrolled in HIV treatment who started treatment for latent TB infection
hiv_reg		Total number of people registered as HIV-positive regardless of year of diagnosis. (Total number of adults and children enrolled in HIV care; includes everyone in the HIV care and/or ART register)
hiv_reg_all		Number of adults and children currently enrolled in HIV treatment during the year.
hiv_reg_new		Number of adults and children newly enrolled in HIV treatment  (i.e. those who registered for antiretroviral therapy) during the reporting period
hiv_reg_new2		Total number of adults and children newly enrolled in HIV treatment  (i.e. those who registered for antiretroviral therapy) during the reporting period
hiv_tbdetect		Total number of adults and children newly enrolled in HIV treatment who are diagnosed as having active TB disease during the reporting period
hiv_tbscr		Number of adults and children enrolled in HIV care who had their TB status assessed and recorded during their last visit
hivtest		TB patients (new and re-treatment) with an HIV test result recorded in the TB register
hivtest_pos		TB patients (new and re-treatment) recorded as HIV-positive
mdr_shortreg_tx		Number of patients started on shorter MDR-TB treatment regiments during the reporting year
mdr_shortreg_used	0=No; 1=Yes; 3=Don't know	Had any patients been started on shorter MDR-TB treatment regimens by the end of the reporting year?
mdr_tx_adsm		Number of patients actively monitored for adverse events while on MDR-TB treatment in the reporting year
mdr_tx_adverse_events		Number of patients on MDR-TB treatment who had adverse events registered in the reporting year
mdrxdr_alloral_tx		Number of patients started on all oral longer MDR-TB treatment regimens during the reporting year
mdrxdr_alloral_used	0=No; 1=Yes; 3=Don't know	Had any patients been started on all oral longer MDR-TB treatment regimens by the end of reporting year?
mdrxdr_bdq_tx		Number of patients started on Bedaquiline during the reporting year
mdrxdr_bdq_used	0=No; 1=Yes; 3=Don't know	Had any TB patients been started on Bedaquiline for the treatment of MDR-/XDR-TB by the end of reporting year as part of expanded access, compassionate use or under normal programmatic use, whether in the public or private sector?
mdrxdr_dlm_tx		Number of patients started on Delamanid during the reporting year
mdrxdr_dlm_used	0=No; 1=Yes; 3=Don't know	Had any TB patients been started on Delamanid for the treatment of MDR-/XDR-TB by the end of reporting as part of expanded access, compassionate use or under normal programmatic use, whether in the public or private sector?
new_clindx		New pulmonary clinically diagnosed TB cases (not bacteriologically confirmed as positive for TB, but diagnosed with active TB by a clinician or another medical practitioner who has decided to give the patient a full course of TB treatment).  It also includes pulmonary clinically diagnosed cases with unknown previous TB treatment history.
new_ep		New extrapulmonary cases (bacteriologically confirmed or clinically diagnosed). As of 2013 this also includes extrapulmonary cases with unknown previous TB treatment history.
new_ep_f014		New extrapulmonary cases: females aged 0-14 years (not used after 2012)
new_ep_f04		New extrapulmonary cases: females aged 0-4 years (not used after 2012)
new_ep_f1524		New extrapulmonary cases: females aged 15-24 years (not used after 2012)
new_ep_f15plus		New extrapulmonary cases: females aged 15 years and over (not used after 2012)
new_ep_f2534		New extrapulmonary cases: females aged 25-34 years (not used after 2012)
new_ep_f3544		New extrapulmonary cases: females aged 35-44 years (not used after 2012)
new_ep_f4554		New extrapulmonary cases: females aged 45-54 years (not used after 2012)
new_ep_f514		New extrapulmonary cases: females aged 5-14 years (not used after 2012)
new_ep_f5564		New extrapulmonary cases: females aged 55-64 years (not used after 2012)
new_ep_f65		New extrapulmonary cases: females aged 65 years and over (not used after 2012)
new_ep_fu		New extrapulmonary cases: females age unknown (not used after 2012)
new_ep_m014		New extrapulmonary cases: males aged 0-14 years (not used after 2012)
new_ep_m04		New extrapulmonary cases: males aged 0-4 years (not used after 2012)
new_ep_m1524		New extrapulmonary cases: males aged 15-24 years (not used after 2012)
new_ep_m15plus		New extrapulmonary cases: males aged 15 years and over (not used after 2012)
new_ep_m2534		New extrapulmonary cases: males aged 25-34 years (not used after 2012)
new_ep_m3544		New extrapulmonary cases: males aged 35-44 years (not used after 2012)
new_ep_m4554		New extrapulmonary cases: males aged 45-54 years (not used after 2012)
new_ep_m514		New extrapulmonary cases: males aged 5-14 years (not used after 2012)
new_ep_m5564		New extrapulmonary cases: males aged 55-64 years (not used after 2012)
new_ep_m65		New extrapulmonary cases: males aged 65 years and over (not used after 2012)
new_ep_mu		New extrapulmonary cases: males age unknown (not used after 2012)
new_ep_sexunk014		New extrapulmonary cases: sex unknown, aged 0-14 years (not used after 2012)
new_ep_sexunk04		New extrapulmonary cases: sex unknown, aged 0-4 years (not used after 2012)
new_ep_sexunk15plus		New extrapulmonary cases: sex unknown, aged 15 years and over (not used after 2012)
new_ep_sexunk514		New extrapulmonary cases: sex unknown, aged 5-14 years (not used after 2012)
new_ep_sexunkageunk		New extrapulmonary cases: sex unknown, age unknown (not used after 2012)
new_labconf		New pulmonary bacteriologically confirmed TB cases (smear positive or culture positive or positive by WHO-recommended rapid diagnostics such as Xpert MTB/RIF). As of 2013 this also includes pulmonary bacteriologically confirmed cases with unknown previous TB treatment history.
new_oth		Other new cases (not used after 2012)
new_sn		New pulmonary smear-negative cases (not used after 2012)
new_sn_f014		New pulmonary smear negative/smear unknown/smear not done cases: females aged 0-14 years (not used after 2012)
new_sn_f04		New pulmonary smear negative/smear unknown/smear not done cases: females aged 0-4 years (not used after 2012)
new_sn_f1524		New pulmonary smear negative/smear unknown/smear not done cases: females aged 15-24 years (not used after 2012)
new_sn_f15plus		New pulmonary smear negative/smear unknown/smear not done cases: females aged 15 years and over (not used after 2012)
new_sn_f2534		New pulmonary smear negative/smear unknown/smear not done cases: females aged 25-34 years (not used after 2012)
new_sn_f3544		New pulmonary smear negative/smear unknown/smear not done cases: females aged 35-44 years (not used after 2012)
new_sn_f4554		New pulmonary smear negative/smear unknown/smear not done cases: females aged 45-54 years (not used after 2012)
new_sn_f514		New pulmonary smear negative/smear unknown/smear not done cases: females aged 5-14 years (not used after 2012)
new_sn_f5564		New pulmonary smear negative/smear unknown/smear not done cases: females aged 55-64 years (not used after 2012)
new_sn_f65		New pulmonary smear negative/smear unknown/smear not done cases: females aged 65 years and over (not used after 2012)
new_sn_fu		New pulmonary smear negative/smear unknown/smear not done cases: females age unknown (not used after 2012)
new_sn_m014		New pulmonary smear negative/smear unknown/smear not done cases: males aged 0-14 years (not used after 2012)
new_sn_m04		New pulmonary smear negative/smear unknown/smear not done cases: males aged 0-4 years (not used after 2012)
new_sn_m1524		New pulmonary smear negative/smear unknown/smear not done cases: males aged 15-24 years (not used after 2012)
new_sn_m15plus		New pulmonary smear negative/smear unknown/smear not done cases: males aged 15 years and above (not used after 2012)
new_sn_m2534		New pulmonary smear negative/smear unknown/smear not done cases: males aged 25-34 years (not used after 2012)
new_sn_m3544		New pulmonary smear negative/smear unknown/smear not done cases: males aged 35-44 years (not used after 2012)
new_sn_m4554		New pulmonary smear negative/smear unknown/smear not done cases: males aged 45-54 years (not used after 2012)
new_sn_m514		New pulmonary smear negative/smear unknown/smear not done cases: males aged 5-14 years (not used after 2012)
new_sn_m5564		New pulmonary smear negative/smear unknown/smear not done cases: males aged 55-64 years (not used after 2012)
new_sn_m65		New pulmonary smear negative/smear unknown/smear not done cases: males aged 65 years and over (not used after 2012)
new_sn_mu		New pulmonary smear negative/smear unknown/smear not done cases: males age unknown (not used after 2012)
new_sn_sexunk014		New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, aged 0-14 years (not used after 2012)
new_sn_sexunk04		New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, aged 0-4 years (not used after 2012)
new_sn_sexunk15plus		New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, aged 15 years and over (not used after 2012)
new_sn_sexunk514		New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, aged 5-14 years (not used after 2012)
new_sn_sexunkageunk		New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, age unknown (not used after 2012)
new_sp		New pulmonary smear-positive cases (not used after 2012)
new_sp_f014		New pulmonary smear positive cases: females aged 0-14 years (not used after 2012)
new_sp_f04		New pulmonary smear positive cases: females aged 0-4 years (not used after 2012)
new_sp_f1524		New pulmonary smear positive cases: females aged 15-24 years (not used after 2012)
new_sp_f2534		New pulmonary smear positive cases: females aged 25-34 years (not used after 2012)
new_sp_f3544		New pulmonary smear positive cases: females aged 35-44 years (not used after 2012)
new_sp_f4554		New pulmonary smear positive cases: females aged 45-54 years (not used after 2012)
new_sp_f514		New pulmonary smear positive cases: females aged 5-14 years (not used after 2012)
new_sp_f5564		New pulmonary smear positive cases: females aged 55-64 years (not used after 2012)
new_sp_f65		New pulmonary smear positive cases: females aged 65 and over (not used after 2012)
new_sp_fu		New pulmonary smear positive cases: females age unknown (not used after 2012)
new_sp_m014		New pulmonary smear positive cases: males aged 0-14 years (not used after 2012)
new_sp_m04		New pulmonary smear positive cases: males aged 0-4 years (not used after 2012)
new_sp_m1524		New pulmonary smear positive cases: males aged 15-24 years (not used after 2012)
new_sp_m2534		New pulmonary smear positive cases: males aged 25-34 years (not used after 2012)
new_sp_m3544		New pulmonary smear positive cases: males aged 35-44 years (not used after 2012)
new_sp_m4554		New pulmonary smear positive cases: males aged 45-54 years (not used after 2012)
new_sp_m514		New pulmonary smear positive cases: males aged 5-14 years (not used after 2012)
new_sp_m5564		New pulmonary smear positive cases: males aged 55-64 years (not used after 2012)
new_sp_m65		New pulmonary smear positive cases: males aged 65 years and over (not used after 2012)
new_sp_mu		New pulmonary smear positive cases: males age unknown (not used after 2012)
new_su		New pulmonary smear unknown/not done cases
newinc_rdx		(if rdx_data_available=60) Number of new and relapse cases notified and tested using a WHO-recommended rapid diagnostic (for example Xpert MTB/RIF) at the time of TB diagnosis (regardless of test result)
newrel_art		HIV-positive new and relapse (or all, if newrel_tbhiv_flg = 0 and year > 2015) TB patients started or continued on antiretroviral therapy
newrel_f014		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 0-14 years
newrel_f04		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 0-4 years
newrel_f1014		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 10-14 years
newrel_f1519		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 15-19 years
newrel_f1524		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 15-24 years
newrel_f15plus		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 15 years and over
newrel_f2024		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 20-24 years
newrel_f2534		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 25-34 years
newrel_f3544		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 35-44 years
newrel_f4554		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 45-54 years
newrel_f514		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 5-14 years
newrel_f5564		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 55-64 years
newrel_f59		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 5-9 years
newrel_f65		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 65 years and over
newrel_fu		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females age unknown
newrel_hivpos		Number of new and relapse  (or all, if newrel_tbhiv_flg = 0 and year > 2015) TB patients recorded as HIV-positive
newrel_hivtest		Number of new and relapse (or all, if newrel_tbhiv_flg = 0 and year > 2015) TB patients tested for HIV at the time of TB diagnosis or with known HIV status at the time of TB diagnosis
newrel_m014		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 0-14 years
newrel_m04		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 0-4 years
newrel_m1014		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 10-14 years
newrel_m1519		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 15-19 years
newrel_m1524		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 15-24 years
newrel_m15plus		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 15 years and over
newrel_m2024		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 20-24 years
newrel_m2534		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 25-34 years
newrel_m3544		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 35-44 years
newrel_m4554		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 45-54 years
newrel_m514		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 5-14 years
newrel_m5564		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 55-64 years
newrel_m59		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 5-9 years
newrel_m65		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 65 years and over
newrel_mu		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males age unknown
newrel_sexunk014		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, aged 0-14 years
newrel_sexunk04		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, aged 0-4 years
newrel_sexunk15plus		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, aged 15 years and over
newrel_sexunk514		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, aged 5-14 years
newrel_sexunkageunk		New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, age unknown
newrel_tbhiv_flg	0=No; 1=Yes.	Are data on HIV testing, HIV positivity and provision of antiretroviral therapy (ART) restricted to new and relapse TB cases only?
newret_oth		Other cases not included in new and re-treatment case numbers
notif_foreign		New and re-treatment TB cases among foreign-born individuals
rdst_new		Number of TB cases (pulmonary or extrapulmonary) tested for susceptibility to rifampicin using phenotypic DST or WHO-recommended rapid molecular diagnostics (e.g. Xpert MTB/RIF), before or after starting treatment: new cases
rdst_ret		Number of TB cases (pulmonary or extrapulmonary) tested for susceptibility to rifampicin using phenotypic DST or WHO-recommended rapid molecular diagnostics (e.g. Xpert MTB/RIF), before or after starting treatment: previously treated cases
rdst_unk		Number of TB cases (pulmonary or extrapulmonary) tested for susceptibility to rifampicin using phenotypic DST or WHO-recommended rapid molecular diagnostics (e.g. Xpert MTB/RIF), before or after starting treatment: cases with unknown previous TB treatment history
rdx_data_available	0=No; 60= Yes available from the routine surveillance system; 61=Yes estimated from a review of a random sample of medical records or treatment cards of TB patients representative of the national TB patient population	Are data available on the number of new and relapse cases tested using a WHO-recommended rapid diagnostic during the reporting year?
rdxsurvey_newinc		(if rdx_data_available=61) Number of new and relapse cases whose medical records or treatment cards were included in the survey
rdxsurvey_newinc_rdx		(if rdx_data_available=61) Among the cases reported in rdxsurvey_newinc the number tested using a WHO-recommended rapid diagnostic (such as Xpert MTB/RIF) at the time of TB diagnosis (regardless of test result)
rel_in_agesex_flg	0=No; 1=Yes.	Are all relapse cases included with new cases in the disaggregations by age and sex?
ret_nrel		Previously treated patients, excluding relapse cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed)
ret_oth		Other re-treatment cases
ret_rel		Relapse cases
ret_rel_clindx		Relapse pulmonary clinically diagnosed TB cases (not bacteriologically confirmed as positive for TB, but diagnosed with active TB by a clinician or another medical practitioner who has decided to give the patient a full course of TB treatment).
ret_rel_ep		Relapse extrapulmonary cases (bacteriologically confirmed or clinically diagnosed)
ret_rel_labconf		Relapse  pulmonary bacteriologically confirmed TB cases (smear positive or culture positive or positive by WHO-recommended rapid diagnostics such as Xpert MTB/RIF).
ret_tad		Treatment after default cases
ret_taf		Treatment after failure cases
rr_sldst		Number of laboratory-confirmed RR-TB or MDR-TB cases tested for susceptibility to second-line drugs (fluoroquinolones and second-line injectable agents)
rrmdr_014_tx		The number of children aged 0-14 years among patients who started treatment for MDR-TB (regardless of whether rifampicin resistance was confirmed)
unconf_mdr_tx		Number of MDR-TB (not laboratory-confirmed) patients who started treatment for MDR-TB
unconf_rrmdr_tx		Number of patients (not laboratory-confirmed as having rifampicin-resistant (RR-TB) or multidrg-resistant TB (MDR-TB)) who started treatment for MDR-TB
c_new_snep_tsr		Treatment success rate for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases, percent  (not used after 2011)
c_new_sp_tsr		Treatment success rate for new pulmonary smear-positive (and/or culture-positive) cases, percent  (not used after 2011)
c_new_tsr		Treatment success rate for all new cases (including relapse cases if rel_with_new_flg = 1), percent
c_newrel_014_tsr		Treatment success rate for new and relapse cases in children aged 0-14 years, percent
c_ret_tsr		Treatment success rate for re-treatment cases (excluding relapse cases if rel_with_new_flg = 1), percent
c_tbhiv_tsr		Treatment success rate for HIV-positive TB cases, percent
hiv_new_snep_cmplt		Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: completed  (not used after 2011)
hiv_new_snep_coh		Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: cohort size  (not used after 2011)
hiv_new_snep_def		Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: defaulted  (not used after 2011)
hiv_new_snep_died		Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: died  (not used after 2011)
hiv_new_snep_fail		Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: failed (not used after 2011)
hiv_new_sp_cmplt		Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: completed (not used after 2011)
hiv_new_sp_coh		Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: cohort size (not used after 2011)
hiv_new_sp_cur		Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: cured (not used after 2011)
hiv_new_sp_def		Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: defaulted (not used after 2011)
hiv_new_sp_died		Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: died (not used after 2011)
hiv_new_sp_fail		Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: failed (not used after 2011)
hiv_ret_cmplt		Outcomes for re-treatment HIV-positive TB cases: completed (not used after 2011)
hiv_ret_coh		Outcomes for re-treatment HIV-positive TB cases: cohort size (not used after 2011)
hiv_ret_cur		Outcomes for re-treatment HIV-positive TB cases: cured (not used after 2011)
hiv_ret_def		Outcomes for re-treatment HIV-positive TB cases: defaulted (not used after 2011)
hiv_ret_died		Outcomes for re-treatment HIV-positive TB cases: died (not used after 2011)
hiv_ret_fail		Outcomes for re-treatment HIV-positive TB cases: failed (not used after 2011)
mdr_coh		Outcomes for MDR-TB cases: cohort size
mdr_died		Outcomes for MDR-TB cases: died
mdr_fail		Outcomes for MDR-TB cases: treatment failed
mdr_lost		Outcomes for MDR-TB cases: lost to follow-up
mdr_succ		Outcomes for MDR-TB cases: treatment success (Cured or treatment completed)
new_snep_cmplt		Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: completed (not used after 2011)
new_snep_coh		Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: cohort size (not used after 2011)
new_snep_def		Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: defauled (not used after 2011)
new_snep_died		Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: died (not used after 2011)
new_snep_fail		Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: failed (not used after 2011)
new_sp_cmplt		Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: completed (not used after 2011)
new_sp_coh		Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: cohort size (not used after 2011)
new_sp_cur		Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: cured (not used after 2011)
new_sp_def		Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: defaulted (not used after 2011)
new_sp_died		Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: died (not used after 2011)
new_sp_fail		Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: failed (not used after 2011)
newrel_014_coh		Outcomes for new and relapse cases in children aged 0-14 years: cohort size
newrel_014_died		Outcomes for new and relapse cases in children aged 0-14 years: died
newrel_014_fail		Outcomes for new and relapse cases in children aged 0-14 years: treatment failed
newrel_014_lost		Outcomes for new and relapse cases in children aged 0-14 years: lost to follow-up
newrel_014_succ		Outcomes for new and relapse cases in children aged 0-14 years: treatment success
newrel_coh		Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): cohort size
newrel_died		Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): died
newrel_fail		Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): treatment failed
newrel_lost		Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): lost to follow-up
newrel_succ		Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): treatment success (cured or treatment completed)
rel_with_new_flg	0=No; 1=Yes;	Are outcomes of relapse cases included in the newrel outcome variables?
rep_meth	100=smear;101=culture;102=smear or culture;	Method of confirmation used to report treatment outcomes of pulmonary cases  (not used after 2011)
ret_cmplt		Outcomes for re-treatment cases: completed  (not used after 2011)
ret_coh		Outcomes for re-treatment cases: cohort size (not used after 2011)
ret_cur		Outcomes for re-treatment cases: cured (not used after 2011)
ret_def		Outcomes for re-treatment cases: defaulted (not used after 2011)
ret_died		Outcomes for re-treatment cases: died (not used after 2011)
ret_fail		Outcomes for re-treatment cases: failed (not used after 2011)
ret_nrel_coh		Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): cohort size
ret_nrel_died		Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): died
ret_nrel_fail		Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): treatment failed
ret_nrel_lost		Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): lost to follow-up
ret_nrel_succ		Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): treatment success (cured or treatment completed)
tbhiv_coh		Outcomes for HIV-positive TB cases, all types: cohort size
tbhiv_died		Outcomes for HIV-positive TB cases, all types: died
tbhiv_fail		Outcomes for HIV-positive TB cases, all types: treatment failed
tbhiv_lost		Outcomes for HIV-positive TB cases, all types: lost to follow-up
tbhiv_succ		Outcomes for HIV-positive TB cases, all types: treatment success (cured or treatment completed)
xdr_coh		Outcomes for XDR-TB cases: cohort size
xdr_died		Outcomes for XDR-TB cases: number died
xdr_fail		Outcomes for XDR-TB cases: number whose treatment failed
xdr_lost		Outcomes for XDR-TB cases: lost to follow-up
xdr_succ		Outcomes for XDR-TB cases: treatment success (Cured or treatment completed)
caseb_err_nat	0=No; 42=Yes (all TB patients in the country); 43=Yes (but only for MDR-TB patients countrywide)	Did the National Treatment Programme keep (or have access to) an electronic case-based database for TB patients on treatment at national level
digital_adherence_support	3=don't know; 210=Not used by any treatment centre; 211=Used only by public sector treatment centres; 212=Used only by private sector treatment centres; 213=Used by public and private  sector treatment centres	Did any treatment centre use digital technologies such as short text messaging via mobile phones, video-communication or electronic medication monitors to support TB medication adherence in patients at risk of interrupting treatment?
free_dx_followup	0=No; 1=yes	Does national policy indicate that TB diagnostic and follow-up tests provided through the national TB programme are free of charge or that fees can be fully reimbursed through health insurance, or both, for all people with signs or symptoms of TB?
hcw_tb_infected		Number of health-care workers who had TB
hcw_tot		Total number of health-care workers who were working in the country in the public and private sector
lf_urine_lam	0=No; 1=yes	Does national policy and the diagnostic algorithm indicate the use of the lateral flow urine lipoarabinomannan assay (LF-LAM) to assist in the detection of TB in people living with HIV?
mdrxdr_fail_morphine		Number of patients who started second-line TB treatment 3 years previously whose treatment failed and who received oral morphine by prescription to treat pain or terminal dyspnoea
priv_new_dx		Number of new cases of TB diagnosed according to National Treatment Programme (NTP)  guidelines by private providers
pub_new_dx		Number of new cases of TB diagnosed according to National Treatment Programme (NTP)  guidelines by non-NTP public providers
universal_dst	0=No; 1=yes	Does national policy and the diagnostic algorithm indicate there is universal access to drug susceptibility testing?
wrd_initial_test	0=No; 1=yes	Does national policy and the diagnostic algorithm indicate a WHO-recommended rapid diagnostic as the initial diagnostic test for all people with signs or symptoms of TB?
ep_spec_available	0=No; 1=Yes; 2=Not applicable	Are data available on the number of bacteriologically confirmed extrapulmonary TB cases with test results for the speciation of the Mycobacterium tuberculosis complex in the reporting year?
newrel_ep_labconf		(if ep_spec_available=1) Among the new and relapse extrapulmonary TB cases reported in new_ep and ret_rel_ep, the number of cases that were bacteriologically confirmed, i.e. by culture or molecular technologies
newrel_ep_mbovis		(if ep_spec_available=1) Among extrapulmonary TB cases with test results for speciation reported in newrel_ep_spec, number of cases identified as having Mycobacterium bovis
newrel_ep_spec		(if ep_spec_available=1) Among bacteriologically confirmed extrapulmonary TB cases reported in newrel_ep_labconf, number of cases with test results for the speciation of the Mycobacterium tuberculosis complex
newrel_pulm_mbovis		(if pulm_spec_available=1) Among pulmonary cases with test results for speciation reported in newrel_pulm_spec, number of cases identified as having Mycobacterium bovis
newrel_pulm_spec		(if pulm_spec_available=1) Among bacteriologically confirmed new and relapse pulmonary TB cases, number of cases with test results for the speciation of the Mycobacterium tuberculosis complex
pulm_spec_available	0=No; 1=Yes; 2=Not applicable	Are data available on the number of bacteriologically confirmed pulmonary TB cases with test results for the speciation of the Mycobacterium tuberculosis complex in the reporting year?
